Страна: Канада
мова: англійська
Джерело: Health Canada
COAGULATION FACTOR IX (RECOMBINANT); WATER
WYETH CANADA
B02BD04
COAGULATION FACTOR IX
500UNIT; 5ML
KIT
COAGULATION FACTOR IX (RECOMBINANT) 500UNIT; WATER 5ML
INTRAVENOUS
PACKAGED AS A KIT
Schedule D
HEMOSTATICS
Active ingredient group (AIG) number: 0233010002; AHFS:
CANCELLED POST MARKET
2008-06-19
PRODUCT MONOGRAPH BENEFIX ® COAGULATION FACTOR IX (RECOMBINANT) INN= NONACOG ALFA BENEFIX ® COAGULATION FACTOR IX (RECOMBINANT), IS PREPARED IN FOUR LYOPHILIZED POWDER DOSAGE FORMS NOMINALLY CONTAINING 250, 500, 1000 AND 2000 IU PER VIAL. THE RECONSTITUTED PRODUCT CONTAINS APPROXIMATELY: 50, 100, 200 AND 400 IU/ML, RESPECTIVELY. WORLD HEALTH ORGANIZATION (WHO) INTERNATIONAL STANDARD FOR FACTOR IX CONCENTRATE ANTIHEMORRHAGIC BLOOD COAGULATION FACTOR IX ©WYETH CANADA, MONTREAL, CANADA DATE OF APPROVAL: MARCH 21, 1997 DATE OF REVISION: APRIL 5, 2007 CONTROL#: 105598 DATE OF APPROVAL: APRIL 13, 2007 _ _ _ _ _Page 2 of 31 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ........................................................ 3 SUMMARY PRODUCT INFORMATION ............................................................................ 3 INDICATIONS AND CLINICAL USE .................................................................................. 3 CONTRAINDICATIONS ........................................................................................................ 4 WARNINGS AND PRECAUTIONS ...................................................................................... 4 ADVERSE REACTIONS ......................................................................................................... 7 DRUG INTERACTIONS ....................................................................................................... 11 DOSAGE AND ADMINISTRATION .................................................................................. 11 OVERDOSAGE ...................................................................................................................... 14 ACTION AND CLINICAL PHARMACOLOGY ............................................................... 14 STORAGE AND STABILITY ............................................................................................... 16 SPECIAL HANDLING INSTRUCTIONS ........................................................................... 16 DOSAGE FORMS, C Прочитайте повний документ